[ad_1]
441 Morgan Ave. is DivcoWest’s fifth life science building within Cambridge Crossing. Image courtesy of DivcoWest
Astellas Pharma Inc. has signed a 62,000-square-foot lease at 441 Morgan Ave., in Cambridge, Mass. Currently underway, the 375,000-square-foot, Class A life science facility is part of DivcoWest’s six-building mixed-use Cambridge Crossing development.
Transwestern negotiated on behalf of the tenant, that will occupy two floors at the property, with moving-in scheduled in 2024. The office and lab building topped out in late 2022, with $401.4 million in construction financing provided by KKR, CommercialEdge data shows.
Designed by Ennead and Jacobs Consulting and targeting LEED Gold and WiredScore Platinum certifications, the 14-story 441 Morgan Ave. project is the fifth lab building within the development. The property will include five outdoor terraces, a 5-acre common-area park, three underground parking levels, bike storage facilities and integrated building technologies.
Located close to Interstate 93 and to multiple bus and train stations, the site is close to Kendall Square, while also being 2 miles from downtown Boston through Craigie Drawbridge and 3 miles from Boston Logan International Airport.
Transwestern’s team of Executive Vice Presidents Kyle Robbins and David Burkards, together with Executive Managing Director Andrew Davidson represented Astellas in the lease negotiations.
Developing life science space within Boston
At full build-out, DivcoWest’s Cambridge Crossing will total 4.5 million square feet of residential, retail, office and life sciences space. The development currently has 2.1 million square feet of space completed or under construction and is home to Cerevel Therapeutics and Philips North American Research Center.
Earlier in June, Skanska announced plans to develop a research center for Simmons University, in the Longwood Medical area of Boston. The $311 million project will total 398,000 square feet of office and residential space.
[ad_2]
Source link
